How to Know Insulin Resistance Is Reversing: 7 Signs

Domenic Pisanelli, BHSc Naturopathy | ATMS Registered | Vital Health & Natural Medicine, Melbourne

25+ Years Clinical Experience · Metabolic Health, Hormonal Health, Chronic Fatigue

In 25 years of clinical practice, the pattern of recovery from insulin resistance is remarkably consistent — and it's almost nothing like what people expect. The first signs don't appear on a blood test. They appear in how you feel between meals at week three. The lab markers follow weeks later. And the thing most patients are watching — their weight — is the last thing that moves, and the least reliable indicator that anything is changing.

This article maps the seven signs of genuine insulin resistance reversal in the order they typically appear. Both the subjective ones you'll notice day-to-day, and the clinical markers worth measuring to confirm what's happening beneath the surface. Knowing both is what separates people who give up at six weeks — convinced nothing is working — from those who see the process through to full metabolic recovery.

The Recovery Markers — Early, Improving, and Optimal

Here's what each key marker looks like at different stages of insulin resistance and recovery. Use this as a reference against your own results.

Functional medicine reference ranges used in clinical practice. Not standard Australian laboratory ranges. All results should be interpreted alongside full clinical history.

What the Recovery Timeline Actually Looks Like

The sequence below is what I see in clinical practice with a well-structured protocol. Individual variation exists — but the order is remarkably consistent.

The Problem with "Normal" Blood Sugar

Most standard blood panels for metabolic health measure two things: fasting glucose and HbA1c. Both are late-stage markers. Glucose doesn't start rising until insulin resistance has been present long enough — sometimes a decade or more — for the pancreas to begin losing the ability to compensate. By the time fasting glucose is elevated, you've been insulin resistant for years.

This is the core clinical problem: people with significant insulin resistance are told their metabolic health is fine, because no one ordered the marker that would have caught it. Fasting insulin — the amount of insulin the pancreas needs to produce to maintain normal glucose — rises steadily as cells become resistant to its signal. It's elevated long before glucose moves. And it's not on a standard Medicare panel.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a calculated index using both fasting insulin and fasting glucose together. It is the most sensitive tool available for identifying insulin resistance in its early and middle stages — and it's the primary marker I use to track recovery.

This is the most important marker of genuine metabolic recovery — and the one most likely to move before you feel any different. When insulin sensitivity is improving, the pancreas needs to produce less insulin to achieve the same blood glucose control. Fasting insulin drops. HOMA-IR follows.

In clinical practice, I order fasting insulin and HOMA-IR as baseline markers before any protocol begins, then repeat them at 8–12 weeks. This is where patients often first see objective confirmation that what they're doing is working — sometimes weeks before weight changes or subjective energy improvements become significant.

The goal is to watch fasting insulin and HOMA-IR, not fasting glucose alone. Glucose is the last thing to move. Insulin is the first.

HOMA-IR at a Glance

Where does your HOMA-IR sit? The bars below show the clinical significance at each level.

HOMA-IR = (fasting insulin µIU/mL × fasting glucose mmol/L) ÷ 22.5  ·  Not on standard Australian Medicare panels — request as private pathology

This is usually the first thing patients notice subjectively — and it typically appears within two to four weeks of meaningful dietary change, well before any lab result shifts.

When cells are resistant to insulin, glucose can't enter them efficiently. The result is a pattern of blood sugar spikes after carbohydrate consumption, followed by reactive dips that trigger counter-regulatory hormone release — cortisol, adrenaline, glucagon — which drive fatigue, irritability, and intense carbohydrate cravings. Most patients describe this as the "3pm crash" or feeling shaky, foggy, or irritable when they go more than a few hours without eating.

As insulin sensitivity improves, cells respond to normal insulin levels more efficiently. Blood glucose remains more stable after meals. The pancreas doesn't need to overshoot with insulin. Counter-regulatory swings diminish. Patients notice they can go four, five, or six hours between meals without their energy collapsing or their mood deteriorating. That previously essential afternoon snack becomes unnecessary.

The relationship between insulin resistance and poor sleep runs in both directions — disrupted sleep worsens insulin sensitivity, and insulin resistance disrupts sleep architecture. The early-morning waking pattern I see most often in insulin-resistant patients is a direct consequence of nocturnal blood glucose instability: a drop in glucose during sleep triggers a cortisol and adrenaline response that wakes them, often between 2 and 4am, with a racing mind or a vague sense of anxiety.

As insulin sensitivity improves and blood glucose becomes more stable overnight, this pattern resolves — often before patients have made any deliberate changes to sleep hygiene. They simply wake up less. Fall back to sleep more easily. Stop experiencing that wired-but-exhausted 6am feeling.

Improving sleep quality also accelerates the metabolic recovery process. Growth hormone secretion — which is central to insulin sensitivity and muscle metabolism — occurs primarily during deep sleep stages. Poor sleep reduces this secretion, impairing the very mechanism most needed for recovery. Getting the sleep right is not supplementary to insulin resistance treatment. It is part of it.

Visceral adipose tissue — fat deposited within and around the abdominal organs — is both a consequence and a driver of insulin resistance. It is metabolically active in a way that subcutaneous fat is not: it produces inflammatory cytokines, free fatty acids, and adipokines that directly impair insulin receptor function throughout the body. Reducing visceral fat is one of the most powerful levers available for improving insulin sensitivity.

Waist circumference is a better proxy for visceral fat than weight or BMI. The clinical thresholds used in Australian practice are above 94cm for men and above 80cm for women as markers of elevated metabolic risk. Reduction in waist circumference — even before significant scale weight loss — indicates that visceral fat is being mobilised. This typically becomes measurable at 6–10 weeks of a well-structured protocol.

I tell patients to measure their waist weekly, at the same time of day, before eating. Not to watch weight — weight is noisy and fluctuates. Waist circumference trends in one direction when the protocol is working. That trend is visible earlier and more reliably than scale weight.

The lipid panel is one of the most underutilised metabolic recovery markers. Most people focus on total cholesterol and LDL — which are poor predictors of insulin resistance reversal. Triglycerides and HDL tell a completely different story.

In insulin resistance, chronic hyperinsulinaemia drives the liver to produce excess triglycerides, while simultaneously reducing HDL production. The result is an elevated triglyceride-to-HDL ratio — a pattern that is a more reliable marker of insulin resistance than fasting glucose alone, and one that responds measurably to dietary change before most other markers.

Clinically, what improving insulin sensitivity looks like on a lipid panel:

Triglycerides respond within four to eight weeks of reduced refined carbohydrate and alcohol intake. They are one of the fastest-moving metabolic markers — and watching them fall is one of the most motivating early signs that the protocol is working. If triglycerides aren't moving after eight weeks of consistent dietary change, that's clinically significant information. It points toward either incomplete dietary adherence, a persistent gut driver, elevated stress hormones, or a thyroid issue impairing fat metabolism.

This is one of the clearest subjective indicators that insulin sensitivity is genuinely improving — and one of the most motivating when patients notice it.

Intense carbohydrate cravings are not a character flaw or a lack of willpower. They are a physiological consequence of blood glucose instability and chronic hyperinsulinaemia. When cells can't use glucose efficiently, the brain signals for more of it. When insulin drives glucose down sharply after a high-carbohydrate meal, the resulting dip triggers dopaminergic drive toward sugar consumption. The cycle is metabolic, not psychological.

As insulin sensitivity improves, glucose enters cells more efficiently. Post-meal glucose dips become less extreme. The dopaminergic drive toward sugar diminishes. Patients describe this as: "I can walk past the chocolate now without it being a battle." That's not willpower improving. That's insulin physiology normalising.

The brain runs on glucose and is exquisitely sensitive to the blood glucose instability that accompanies insulin resistance. When glucose supply to the brain becomes erratic — driven by the spikes and dips of poor insulin sensitivity — cognitive performance suffers. The clinical picture is familiar: difficulty concentrating, poor word retrieval, mental fatigue that arrives before physical fatigue, and a general sense of cognitive "heaviness."

Research has established that insulin resistance in the brain — sometimes called "type 3 diabetes" in the context of Alzheimer's disease research — impairs neuronal glucose uptake even when blood glucose appears normal. This mechanism is increasingly understood as a contributor to early cognitive decline, and it responds meaningfully to improvements in peripheral insulin sensitivity.

Clinically, cognitive improvement is often the most emotionally significant sign patients notice during recovery. More than energy. More than weight. When the brain fog lifts — when they finish a meeting and still have mental capacity left, when words come easily again — that's the sign that tends to produce the most emotional response. It's not subtle when it happens.

What Recovery Looks Like on Paper

The following is a composite anonymised example showing how a typical marker panel shifts over 12 weeks of a well-structured protocol.

How the ROOT Method™ Tracks Recovery from Insulin Resistance

Recovery from insulin resistance requires a framework — not a checklist. The mistake I see most often is people making dietary changes in isolation, measuring weight as their only metric, and concluding within six weeks that it isn't working. Weight is the noisiest metabolic marker available. It reflects water retention, muscle gain, hormonal fluctuation, and inflammation simultaneously. It is almost never the right primary tracking metric for insulin resistance reversal.

The ROOT Method™ — Review, Order, Observe, Treat — gives the process structure:

• Review: We assess the full clinical picture — symptom timeline, dietary history, sleep, stress, medication history, and any existing results. Insulin resistance rarely presents in isolation; thyroid function, cortisol, gut health, and hormonal status are all assessed at this stage.
• Order: We request the specific markers that standard panels miss — fasting insulin, HOMA-IR, full lipid panel, cortisol awakening response, comprehensive thyroid panel, and inflammatory markers. This establishes the baseline everything else is measured against.
• Observe: We track the seven signs above across the protocol period. Clinical signs (energy, sleep, cravings, cognitive clarity) are tracked weekly. Lab markers are repeated at 8–12 weeks. The combination tells us which levers are working and which drivers need more attention.
• Treat: Protocol adjustments are based on what the data shows. If triglycerides are dropping but HOMA-IR is plateauing, that points to a persistent driver — often stress hormones, a gut health issue, or thyroid function — that needs attention before the metabolic picture fully normalises.

Frequently Asked Questions